TNF-alpha and neuropathic pain--a review

Lawrence Leung, Catherine M Cahill, Lawrence Leung, Catherine M Cahill

Abstract

Tumor necrosis factor alpha (TNF-alpha) was discovered more than a century ago, and its known roles have extended from within the immune system to include a neuro-inflammatory domain in the nervous system. Neuropathic pain is a recognized type of pathological pain where nociceptive responses persist beyond the resolution of damage to the nerve or its surrounding tissue. Very often, neuropathic pain is disproportionately enhanced in intensity (hyperalgesia) or altered in modality (hyperpathia or allodynia) in relation to the stimuli. At time of this writing, there is as yet no common consensus about the etiology of neuropathic pain - possible mechanisms can be categorized into peripheral sensitization and central sensitization of the nervous system in response to the nociceptive stimuli. Animal models of neuropathic pain based on various types of nerve injuries (peripheral versus spinal nerve, ligation versus chronic constrictive injury) have persistently implicated a pivotal role for TNF-alpha at both peripheral and central levels of sensitization. Despite a lack of success in clinical trials of anti-TNF-alpha therapy in alleviating the sciatic type of neuropathic pain, the intricate link of TNF-alpha with other neuro-inflammatory signaling systems (e.g., chemokines and p38 MAPK) has indeed inspired a systems approach perspective for future drug development in treating neuropathic pain.

Figures

Figure 1
Figure 1
The roles of TNF-α as recognized at different levels of the nervous system in neuropathic pain induced by nerve injury: (1) at site of nerve injury; (2) at dorsal root ganglion; (3) at dorsal horn of the spinal cord; and (4) at the brain and higher centres.

References

    1. Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron. 2006;52:77–92. doi: 10.1016/j.neuron.2006.09.021.
    1. McMahon SB, Cafferty WB, Marchand F. Immune and glial cell factors as pain mediators and modulators. Exp Neurol. 2005;192:444–462. doi: 10.1016/j.expneurol.2004.11.001.
    1. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat Rev Neurosci. 2005;6:521–532. doi: 10.1038/nrn1700.
    1. Moalem G, Tracey DJ. Immune and inflammatory mechanisms in neuropathic pain. Brain Res Rev. 2006;51:240–264. doi: 10.1016/j.brainresrev.2005.11.004.
    1. Bowsher D. Neurogenic pain syndromes and their management. Br Med Bull. 1991;47:644–666.
    1. Cartier GT, Galer BS. Advances in the management of neuropathic pain. [Phys Med Rehabil Clin N Am. 2001] - PubMed result. Phys Med Rehabil Clin N Am. 2001;12:447–459.
    1. Toth C, Lander J, Wiebe S. The prevalence and impact of chronic pain with neuropathic pain symptoms in the general population. Pain Med. 2009;10:918–929. doi: 10.1111/j.1526-4637.2009.00655.x.
    1. Mitchell SW. Injuries of nerves and their consequences. Philadelphia, Lippincott. 1872.
    1. Hall GC, Carroll D, Parry D, McQuay HJ. Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain. 2006;122:156–162. doi: 10.1016/j.pain.2006.01.030.
    1. McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain. 2006;10:127–135. doi: 10.1016/j.ejpain.2005.01.014.
    1. O'Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics. 2009;27:95–112. doi: 10.2165/00019053-200927020-00002.
    1. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces d... [Pain. 1988] - PubMed result. Pain. 1988;33:87–107. doi: 10.1016/0304-3959(88)90209-6.
    1. Xie Y, Zhang J, Petersen M, LaMotte RH. Functional changes in dorsal root ganglion cells after chronic nerve constriction in the rat. J Neurophysiol. 1995;73:1811–1820.
    1. Kingery WS, Castellote JM, Wang EE. A loose ligature-induced mononeuropathy produces h... [Pain. 1993] - PubMed result. Pain. 1993;55:297–304. doi: 10.1016/0304-3959(93)90004-9.
    1. Kim KJ, Yoon YW, Chung JM. Comparison of three rodent neuropathic pain models. Exp Brain Res. 1997;113:200–206. doi: 10.1007/BF02450318.
    1. Shir Y, Seltzer Z. A-fibers mediate mechanical hyperesthesia and allo... [Neurosci Lett. 1990] - PubMed result. Neurosci Lett. 1990;115:62–67. doi: 10.1016/0304-3940(90)90518-E.
    1. Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain. 1990;43:205–218. doi: 10.1016/0304-3959(90)91074-S.
    1. Nuytten D, Kupers R, Lammens M, Dom R. Further evidence for myelinated as well as unmyeli... [Exp Brain Res. 1992] - PubMed result. Exp Brain Res. 1992;91:73–78. doi: 10.1007/BF00230014.
    1. Puke MJ, Xu XJ, Wiesenfeld-Hallin Z. Intrathecal administration of clonidine suppresses... [Neurosci Lett. 1991] - PubMed result. Neurosci Lett. 1991;133:199–202. doi: 10.1016/0304-3940(91)90569-F.
    1. Miao P, Madec K, Gong Y, Shen H, Eisenstat D, Melanson M, Gu X, Leong C, Klowak M, Namaka M. Axotomy-induced up-regulation of tumor necrosis factor-alpha in the dorsal root ganglia. Neurol Res. 2008;30:623–631. doi: 10.1179/174313208X289606.
    1. Guedes RP, Araujo AS, Janner D, Bello-Klein A, Ribeiro MF, Partata WA. Increase in reactive oxygen species and activation of Akt signaling pathway in neuropathic pain. Cell Mol Neurobiol. 2008;28:1049–1056. doi: 10.1007/s10571-008-9279-9.
    1. Li L, Xian CJ, Zhong JH, Zhou XF. Effect of lumbar 5 ventral root transection on pain behaviors: a novel rat model for neuropathic pain without axotomy of primary sensory neurons. Exp Neurol. 2002;175:23–34. doi: 10.1006/exnr.2002.7897.
    1. Xu JT, Xin WJ, Zang Y, Wu CY, Liu XG. The role of tumor necrosis factor-alpha in the neuropathic pain induced by Lumbar 5 ventral root transection in rat. Pain. 2006;123:306–321. doi: 10.1016/j.pain.2006.03.011.
    1. Olsson Y. Degranulation of mast cells in peripheral nerve injuries. Acta Neurol Scand. 1967;43:365–374. doi: 10.1111/j.1600-0404.1967.tb05739.x.
    1. Perry VH, Brown MC, Gordon S. The macrophage response to central and peripheral nerve injury. A possible role for macrophages in regeneration. J Exp Med. 1987;165:1218–1223. doi: 10.1084/jem.165.4.1218.
    1. Daemen MA, Kurvers HA, Kitslaar PJ, Slaaf DW, Bullens PH, Wildenberg FA Van den. Neurogenic inflammation in an animal model of neuropathic pain. Neurol Res. 1998;20:41–45.
    1. Maves TJ, Pechman PS, Gebhart GF, Meller ST. Possible chemical contribution from chromic gut sutures produces disorders of pain sensation like those seen in man. Pain. 1993;54:57–69. doi: 10.1016/0304-3959(93)90100-4.
    1. Sommer C, Galbraith JA, Heckman HM, Myers RR. Pathology of experimental compression neuropathy producing hyperesthesia. J Neuropathol Exp Neurol. 1993;52:223–233. doi: 10.1097/00005072-199305000-00006.
    1. Frisen J, Risling M, Fried K. Distribution and axonal relations of macrophages in a neuroma. Neuroscience. 1993;55:1003–1013. doi: 10.1016/0306-4522(93)90314-6.
    1. Clatworthy AL, Illich PA, Castro GA, Walters ET. Role of peri-axonal inflammation in the development of thermal hyperalgesia and guarding behavior in a rat model of neuropathic pain. Neurosci Lett. 1995;184:5–8. doi: 10.1016/0304-3940(94)11154-B.
    1. Schafers M, Marziniak M, Sorkin LS, Yaksh TL, Sommer C. Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat. Exp Neurol. 2004;185:160–168. doi: 10.1016/j.expneurol.2003.09.015.
    1. Ma W, Du W, Eisenach JC. Role for both spinal cord COX-1 and COX-2 in maintenance of mechanical hypersensitivity following peripheral nerve injury. Brain Res. 2002;937:94–99. doi: 10.1016/S0006-8993(02)02593-3.
    1. Syriatowicz JP, Hu D, Walker JS, Tracey DJ. Hyperalgesia due to nerve injury: role of prostaglandins. Neuroscience. 1999;94:587–594. doi: 10.1016/S0306-4522(99)00365-6.
    1. Okubo M, Yamanaka H, Kobayashi K, Noguchi K. Leukotriene synthases and the receptors induced by peripheral nerve injury in the spinal cord contribute to the generation of neuropathic pain. Glia. 2009;58(5):599–610.
    1. Rashid MH, Inoue M, Matsumoto M, Ueda H. Switching of bradykinin-mediated nociception following partial sciatic nerve injury in mice. J Pharmacol Exp Ther. 2004;308:1158–1164. doi: 10.1124/jpet.103.060335.
    1. Petcu M, Dias JP, Ongali B, Thibault G, Neugebauer W, Couture R. Role of kinin B1 and B2 receptors in a rat model of neuropathic pain. Int Immunopharmacol. 2008;8:188–196. doi: 10.1016/j.intimp.2007.09.009.
    1. Berrocoso E, De Benito MD, Mico JA. Role of serotonin 5-HT1A and opioid receptors in the antiallodynic effect of tramadol in the chronic constriction injury model of neuropathic pain in rats. Psychopharmacology (Berl) 2007;193:97–105. doi: 10.1007/s00213-007-0761-8.
    1. Faerber L, Drechsler S, Ladenburger S, Gschaidmeier H, Fischer W. The neuronal 5-HT3 receptor network after 20 years of research--evolving concepts in management of pain and inflammation. Eur J Pharmacol. 2007;560:1–8. doi: 10.1016/j.ejphar.2007.01.028.
    1. Rahman W, Suzuki R, Webber M, Hunt SP, Dickenson AH. Depletion of endogenous spinal 5-HT attenuates the behavioural hypersensitivity to mechanical and cooling stimuli induced by spinal nerve ligation. Pain. 2006;123:264–274. doi: 10.1016/j.pain.2006.02.033.
    1. Inoue K. P2 receptors and chronic pain. Purinergic Signal. 2007;3:135–144. doi: 10.1007/s11302-006-9045-8.
    1. Inoue K, Tsuda M, Koizumi S. ATP- and adenosine-mediated signaling in the central nervous system: chronic pain and microglia: involvement of the ATP receptor P2X4. J Pharmacol Sci. 2004;94:112–114. doi: 10.1254/jphs.94.112.
    1. Inoue K, Tsuda M, Tozaki-Saitoh H. Modification of neuropathic pain sensation through microglial ATP receptors. Purinergic Signal. 2007;3:311–316. doi: 10.1007/s11302-007-9071-1.
    1. Wilson-Gerwing TD, Stucky CL, McComb GW, Verge VM. Neurotrophin-3 significantly reduces sodium channel expression linked to neuropathic pain states. Exp Neurol. 2008;213:303–314. doi: 10.1016/j.expneurol.2008.06.002.
    1. Coull JA, Beggs S, Boudreau D, Boivin D, Tsuda M, Inoue K, Gravel C, Salter MW, De Koninck Y. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature. 2005;438:1017–1021. doi: 10.1038/nature04223.
    1. Boudes M, Menigoz A. Non-neuronal BDNF, a key player in development of central sensitization and neuropathic pain. J Physiol. 2009;587:2111–2112. doi: 10.1113/jphysiol.2009.172130.
    1. Chien CC, Fu WM, Huang HI, Lai YH, Tsai YF, Guo SL, Wu TJ, Ling QD. Expression of neurotrophic factors in neonatal rats after peripheral inflammation. J Pain. 2007;8:161–167. doi: 10.1016/j.jpain.2006.07.004.
    1. Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett. 2004;361:184–187. doi: 10.1016/j.neulet.2003.12.007.
    1. Okamoto K, Martin DP, Schmelzer JD, Mitsui Y, Low PA. Pro- and anti-inflammatory cytokine gene expression in rat sciatic nerve chronic constriction injury model of neuropathic pain. Exp Neurol. 2001;169:386–391. doi: 10.1006/exnr.2001.7677.
    1. Arruda JL, Colburn RW, Rickman AJ, Rutkowski MD, DeLeo JA. Increase of interleukin-6 mRNA in the spinal cord following peripheral nerve injury in the rat: potential role of IL-6 in neuropathic pain. Brain Res Mol Brain Res. 1998;62:228–235. doi: 10.1016/S0169-328X(98)00257-5.
    1. Sommer C, Schmidt C, George A. Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1. Exp Neurol. 1998;151:138–142. doi: 10.1006/exnr.1998.6797.
    1. Watkins LR, Maier SF, Goehler LE. Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Pain. 1995;63:289–302. doi: 10.1016/0304-3959(95)00186-7.
    1. Latremoliere A, Mauborgne A, Masson J, Bourgoin S, Kayser V, Hamon M, Pohl M. Differential implication of proinflammatory cytokine interleukin-6 in the development of cephalic versus extracephalic neuropathic pain in rats. J Neurosci. 2008;28:8489–8501. doi: 10.1523/JNEUROSCI.2552-08.2008.
    1. White FA, Jung H, Miller RJ. Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci USA. 2007;104:20151–20158. doi: 10.1073/pnas.0709250104.
    1. Ma W, Quirion R. Inflammatory mediators modulating the transient receptor potential vanilloid 1 receptor: therapeutic targets to treat inflammatory and neuropathic pain. Expert Opin Ther Targets. 2007;11:307–320. doi: 10.1517/14728222.11.3.307.
    1. Gao X, Kim HK, Chung JM, Chung K. Reactive oxygen species (ROS) are involved in enhancement of NMDA-receptor phosphorylation in animal models of pain. Pain. 2007;131:262–271. doi: 10.1016/j.pain.2007.01.011.
    1. Siniscalco D, Fuccio C, Giordano C, Ferraraccio F, Palazzo E, Luongo L, Rossi F, Roth KA, Maione S, de Novellis V. Role of reactive oxygen species and spinal cord apoptotic genes in the development of neuropathic pain. Pharmacol Res. 2007;55:158–166. doi: 10.1016/j.phrs.2006.11.009.
    1. Bergsteinsdottir K, Kingston A, Jessen KR. Rat Schwann cells can be induced to express major histocompatibility complex class II molecules in vivo. J Neurocytol. 1992;21:382–390. doi: 10.1007/BF01191706.
    1. Constable AL, Armati PJ, Toyka KV, Hartung HP. Production of prostanoids by Lewis rat Schwann cells in vitro. Brain Res. 1994;635:75–80. doi: 10.1016/0006-8993(94)91425-7.
    1. Bolin LM, Verity AN, Silver JE, Shooter EM, Abrams JS. Interleukin-6 production by Schwann cells and induction in sciatic nerve injury. J Neurochem. 1995;64:850–858.
    1. Adler JE, Nico L, VandeVord P, Skoff AM. Modulation of neuropathic pain by a glial-derived factor. Pain Med. 2009;10:1229–1236. doi: 10.1111/j.1526-4637.2009.00708.x.
    1. Hansson E. Could chronic pain and spread of pain sensation be induced and maintained by glial activation? Acta Physiol (Oxf) 2006;187:321–327. doi: 10.1111/j.1748-1716.2006.01568.x.
    1. Moss A, Beggs S, Vega-Avelaira D, Costigan M, Hathway GJ, Salter MW, Fitzgerald M. Spinal microglia and neuropathic pain in young rats. Pain. 2007;128:215–224. doi: 10.1016/j.pain.2006.09.018.
    1. Thacker MA, Clark AK, Bishop T, Grist J, Yip PK, Moon LD, Thompson SW, Marchand F, McMahon SB. CCL2 is a key mediator of microglia activation in neuropathic pain states. Eur J Pain. 2009;13:263–272. doi: 10.1016/j.ejpain.2008.04.017.
    1. Sauder DN. The role of epidermal cytokines in inflammatory skin diseases. J Invest Dermatol. 1990;95:27S–28S. doi: 10.1111/1523-1747.ep12505705.
    1. Compston A, Zajicek J, Sussman J, Webb A, Hall G, Muir D, Shaw C, Wood A, Scolding N. Glial lineages and myelination in the central nervous system. J Anat. 1997;190(Pt 2):161–200. doi: 10.1046/j.1469-7580.1997.19020161.x.
    1. Lisak RP, Skundric D, Bealmear B, Ragheb S. The role of cytokines in Schwann cell damage, protection, and repair. J Infect Dis. 1997;176(Suppl 2):S173–179. doi: 10.1086/513788.
    1. Beeson PB. Temperature-elevating effect of a substance obtained from polymorphonuclear leucocytes. J Clin Invest. 1948;27:524.
    1. Uceyler N, Sommer C. Cytokine regulation in animal models of neuropathic pain and in human diseases. Neurosci Lett. 2008;437:194–198. doi: 10.1016/j.neulet.2008.03.050.
    1. Wagner R, Myers RR. Endoneurial injection of TNF-alpha produces neuropathic pain behaviors. Neuroreport. 1996;7:2897–2901. doi: 10.1097/00001756-199611250-00018.
    1. Wagner R, Myers RR. Schwann cells produce tumor necrosis factor alpha: expression in injured and non-injured nerves. Neuroscience. 1996;73:625–629. doi: 10.1016/0306-4522(96)00127-3.
    1. Zelenka M, Schafers M, Sommer C. Intraneural injection of interleukin-1beta and tumor necrosis factor-alpha into rat sciatic nerve at physiological doses induces signs of neuropathic pain. Pain. 2005;116:257–263. doi: 10.1016/j.pain.2005.04.018.
    1. Sweitzer SM, Colburn RW, Rutkowski M, DeLeo JA. Acute peripheral inflammation induces moderate glial activation and spinal IL-1beta expression that correlates with pain behavior in the rat. Brain Res. 1999;829:209–221. doi: 10.1016/S0006-8993(99)01326-8.
    1. DeLeo JA, Colburn RW, Nichols M, Malhotra A. Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J Interferon Cytokine Res. 1996;16:695–700. doi: 10.1089/jir.1996.16.695.
    1. Wells MR, Racis SP Jr, Vaidya U. Changes in plasma cytokines associated with peripheral nerve injury. J Neuroimmunol. 1992;39:261–268. doi: 10.1016/0165-5728(92)90260-R.
    1. Bickels J, Kollender Y, Merinsky O, Meller I. Coley's toxin: historical perspective. Isr Med Assoc J. 2002;4:471–472.
    1. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975;72:3666–3670. doi: 10.1073/pnas.72.9.3666.
    1. Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci. 2002;27:19–26. doi: 10.1016/S0968-0004(01)01995-8.
    1. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104:487–501. doi: 10.1016/S0092-8674(01)00237-9.
    1. George A, Schmidt C, Weishaupt A, Toyka KV, Sommer C. Serial determination of tumor necrosis factor-alpha content in rat sciatic nerve after chronic constriction injury. Exp Neurol. 1999;160:124–132. doi: 10.1006/exnr.1999.7193.
    1. George A, Buehl A, Sommer C. Wallerian degeneration after crush injury of rat sciatic nerve increases endo- and epineurial tumor necrosis factor-alpha protein. Neurosci Lett. 2004;372:215–219. doi: 10.1016/j.neulet.2004.09.075.
    1. Shubayev VI, Myers RR. Upregulation and interaction of TNFalpha and gelatinases A and B in painful peripheral nerve injury. Brain Res. 2000;855:83–89. doi: 10.1016/S0006-8993(99)02321-5.
    1. Sommer C, Schafers M. Painful mononeuropathy in C57BL/Wld mice with delayed wallerian degeneration: differential effects of cytokine production and nerve regeneration on thermal and mechanical hypersensitivity. Brain Res. 1998;784:154–162. doi: 10.1016/S0006-8993(97)01327-9.
    1. Shamash S, Reichert F, Rotshenker S. The cytokine network of Wallerian degeneration: tumor necrosis factor-alpha, interleukin-1alpha, and interleukin-1beta. J Neurosci. 2002;22:3052–3060.
    1. George A, Buehl A, Sommer C. Tumor necrosis factor receptor 1 and 2 proteins are differentially regulated during Wallerian degeneration of mouse sciatic nerve. Exp Neurol. 2005;192:163–166. doi: 10.1016/j.expneurol.2004.11.002.
    1. Empl M, Renaud S, Erne B, Fuhr P, Straube A, Schaeren-Wiemers N, Steck AJ. TNF-alpha expression in painful and nonpainful neuropathies. Neurology. 2001;56:1371–1377.
    1. Sorkin LS, Doom CM. Epineurial application of TNF elicits an acute mechanical hyperalgesia in the awake rat. J Peripher Nerv Syst. 2000;5:96–100. doi: 10.1046/j.1529-8027.2000.00012.x.
    1. Jin X, Gereau RWt. Acute p38-mediated modulation of tetrodotoxin-resistant sodium channels in mouse sensory neurons by tumor necrosis factor-alpha. J Neurosci. 2006;26:246–255. doi: 10.1523/JNEUROSCI.3858-05.2006.
    1. Yang L, Lindholm K, Konishi Y, Li R, Shen Y. Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways. J Neurosci. 2002;22:3025–3032.
    1. Constantin CE, Mair N, Sailer CA, Andratsch M, Xu ZZ, Blumer MJ, Scherbakov N, Davis JB, Bluethmann H, Ji RR, Kress M. Endogenous tumor necrosis factor alpha (TNFalpha) requires TNF receptor type 2 to generate heat hyperalgesia in a mouse cancer model. J Neurosci. 2008;28:5072–5081. doi: 10.1523/JNEUROSCI.4476-07.2008.
    1. Schafers M, Sommer C, Geis C, Hagenacker T, Vandenabeele P, Sorkin LS. Selective stimulation of either tumor necrosis factor receptor differentially induces pain behavior in vivo and ectopic activity in sensory neurons in vitro. Neuroscience. 2008;157:414–423. doi: 10.1016/j.neuroscience.2008.08.067.
    1. Ohishi S. [Evaluation of time course and inter-relationship of inflammatory mediators in experimental inflammatory reaction] Yakugaku Zasshi. 2000;120:455–462.
    1. Tonini G, Santini D, Vincenzi B, Borzomati D, Dicuonzo G, La Cesa A, Onori N, Coppola R. Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients. J Biol Regul Homeost Agents. 2002;16:105–109.
    1. Drory VE, Lev D, Groozman GB, Gutmann M, Klausner JM. Neurotoxicity of isolated limb perfusion with tumor necrosis factor. J Neurol Sci. 1998;158:1–4. doi: 10.1016/S0022-510X(98)00098-7.
    1. Schafers M, Geis C, Svensson CI, Luo ZD, Sommer C. Selective increase of tumour necrosis factor-alpha in injured and spared myelinated primary afferents after chronic constrictive injury of rat sciatic nerve. Eur J Neurosci. 2003;17:791–804. doi: 10.1046/j.1460-9568.2003.02504.x.
    1. Jancalek R, Dubovy P, Svizenska I, Klusakova I. Bilateral changes of TNF-alpha and IL-10 protein in the lumbar and cervical dorsal root ganglia following a unilateral chronic constriction injury of the sciatic nerve. J Neuroinflammation. 2010;7:11. doi: 10.1186/1742-2094-7-11.
    1. Shubayev VI, Myers RR. Axonal transport of TNF-alpha in painful neuropathy: distribution of ligand tracer and TNF receptors. J Neuroimmunol. 2001;114:48–56. doi: 10.1016/S0165-5728(00)00453-7.
    1. Schafers M, Sorkin LS, Geis C, Shubayev VI. Spinal nerve ligation induces transient upregulation of tumor necrosis factor receptors 1 and 2 in injured and adjacent uninjured dorsal root ganglia in the rat. Neurosci Lett. 2003;347:179–182. doi: 10.1016/S0304-3940(03)00695-5.
    1. Sacerdote P, Franchi S, Trovato AE, Valsecchi AE, Panerai AE, Colleoni M. Transient early expression of TNF-alpha in sciatic nerve and dorsal root ganglia in a mouse model of painful peripheral neuropathy. Neurosci Lett. 2008;436:210–213. doi: 10.1016/j.neulet.2008.03.023.
    1. Cuellar JM, Montesano PX, Carstens E. Role of TNF-alpha in sensitization of nociceptive dorsal horn neurons induced by application of nucleus pulposus to L5 dorsal root ganglion in rats. Pain. 2004;110:578–587. doi: 10.1016/j.pain.2004.03.029.
    1. Shubayev VI, Myers RR. Anterograde TNF alpha transport from rat dorsal root ganglion to spinal cord and injured sciatic nerve. Neurosci Lett. 2002;320:99–101. doi: 10.1016/S0304-3940(02)00010-1.
    1. Schafers M, Lee DH, Brors D, Yaksh TL, Sorkin LS. Increased sensitivity of injured and adjacent uninjured rat primary sensory neurons to exogenous tumor necrosis factor-alpha after spinal nerve ligation. J Neurosci. 2003;23:3028–3038.
    1. Thorburn A. Death receptor-induced cell killing. Cell Signal. 2004;16:139–144. doi: 10.1016/j.cellsig.2003.08.007.
    1. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114:181–190. doi: 10.1016/S0092-8674(03)00521-X.
    1. Joseph EK, Levine JD. Caspase signalling in neuropathic and inflammatory pain in the rat. Eur J Neurosci. 2004;20:2896–2902. doi: 10.1111/j.1460-9568.2004.03750.x.
    1. Sekiguchi M, Sekiguchi Y, Konno S, Kobayashi H, Homma Y, Kikuchi S. Comparison of neuropathic pain and neuronal apoptosis following nerve root or spinal nerve compression. Eur Spine J. 2009;18:1978–1985. doi: 10.1007/s00586-009-1064-z.
    1. Czeschik JC, Hagenacker T, Schafers M, Busselberg D. TNF-alpha differentially modulates ion channels of nociceptive neurons. Neurosci Lett. 2008;434:293–298. doi: 10.1016/j.neulet.2008.01.070.
    1. Watkins LR, Maier SF. The pain of being sick: implications of immune-to-brain communication for understanding pain. Annu Rev Psychol. 2000;51:29–57. doi: 10.1146/annurev.psych.51.1.29.
    1. Ignatowski TA, Covey WC, Knight PR, Severin CM, Nickola TJ, Spengler RN. Brain-derived TNFalpha mediates neuropathic pain. Brain Res. 1999;841:70–77. doi: 10.1016/S0006-8993(99)01782-5.
    1. Covey WC, Ignatowski TA, Knight PR, Spengler RN. Brain-derived TNFalpha: involvement in neuroplastic changes implicated in the conscious perception of persistent pain. Brain Res. 2000;859:113–122. doi: 10.1016/S0006-8993(00)01965-X.
    1. Covey WC, Ignatowski TA, Renauld AE, Knight PR, Nader ND, Spengler RN. Expression of neuron-associated tumor necrosis factor alpha in the brain is increased during persistent pain. Reg Anesth Pain Med. 2002;27:357–366.
    1. Li X, Wang J, Wang Z, Dong C, Dong X, Jing Y, Yuan Y, Fan G. Tumor necrosis factor-alpha of Red nucleus involved in the development of neuropathic allodynia. Brain Res Bull. 2008. in press .
    1. Sanchez I, Hassinger L, Paskevich PA, Shine HD, Nixon RA. Oligodendroglia regulate the regional expansion of axon caliber and local accumulation of neurofilaments during development independently of myelin formation. J Neurosci. 1996;16:5095–5105.
    1. Nadkarni S, Jung P. Modeling synaptic transmission of the tripartite synapse. Phys Biol. 2007;4:1–9. doi: 10.1088/1478-3975/4/1/001.
    1. Stevens B. Neuron-astrocyte signaling in the development and plasticity of neural circuits. Neurosignals. 2008;16:278–288. doi: 10.1159/000123038.
    1. Haydon PG, Carmignoto G. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol Rev. 2006;86:1009–1031. doi: 10.1152/physrev.00049.2005.
    1. Ji RR, Kawasaki Y, Zhuang ZY, Wen YR, Decosterd I. Possible role of spinal astrocytes in maintaining chronic pain sensitization: review of current evidence with focus on bFGF/JNK pathway. Neuron Glia Biol. 2006;2:259–269. doi: 10.1017/S1740925X07000403.
    1. Ji RR, Suter MR. p38 MAPK, microglial signaling, and neuropathic pain. Mol Pain. 2007;3:33. doi: 10.1186/1744-8069-3-33.
    1. De Leo JA, Tawfik VL, LaCroix-Fralish ML. The tetrapartite synapse: path to CNS sensitization and chronic pain. Pain. 2006;122:17–21. doi: 10.1016/j.pain.2006.02.034.
    1. Seth P, Koul N. Astrocyte, the star avatar: redefined. J Biosci. 2008;33:405–421. doi: 10.1007/s12038-008-0060-5.
    1. Vilhardt F. Microglia: phagocyte and glia cell. Int J Biochem Cell Biol. 2005;37:17–21. doi: 10.1016/j.biocel.2004.06.010.
    1. Watkins LR, Maier SF. Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Discov. 2003;2:973–985. doi: 10.1038/nrd1251.
    1. Ren K, Dubner R. Neuron-glia crosstalk gets serious: role in pain hypersensitivity. Curr Opin Anaesthesiol. 2008;21:570–579. doi: 10.1097/ACO.0b013e32830edbdf.
    1. Abbadie C, Bhangoo S, De Koninck Y, Malcangio M, Melik-Parsadaniantz S, White FA. Chemokines and pain mechanisms. Brain Res Rev. 2008;60(1):125–34. doi: 10.1016/j.brainresrev.2008.12.002.
    1. Inoue K, Tsuda M, Koizumi S. Chronic pain and microglia: the role of ATP. Novartis Found Symp. 2004;261:55–64. discussion 64-57, 149-154. full_text.
    1. Tsuda M, Inoue K. [Neuropathic pain and ATP receptors in spinal microglia] Brain Nerve. 2007;59:953–959.
    1. Garrison CJ, Dougherty PM, Kajander KC, Carlton SM. Staining of glial fibrillary acidic protein (GFAP) in lumbar spinal cord increases following a sciatic nerve constriction injury. Brain Res. 1991;565:1–7. doi: 10.1016/0006-8993(91)91729-K.
    1. Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci. 2001;24:450–455. doi: 10.1016/S0166-2236(00)01854-3.
    1. Watkins LR, Hutchinson MR, Milligan ED, Maier SF. "Listening" and "talking" to neurons: implications of immune activation for pain control and increasing the efficacy of opioids. Brain Res Rev. 2007;56:148–169. doi: 10.1016/j.brainresrev.2007.06.006.
    1. Wei F, Guo W, Zou S, Ren K, Dubner R. Supraspinal glial-neuronal interactions contribute to descending pain facilitation. J Neurosci. 2008;28:10482–10495. doi: 10.1523/JNEUROSCI.3593-08.2008.
    1. Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361:31–39. doi: 10.1038/361031a0.
    1. Rygh LJ, Svendsen F, Fiska A, Haugan F, Hole K, Tjolsen A. Long-term potentiation in spinal nociceptive systems--how acute pain may become chronic. Psychoneuroendocrinology. 2005;30:959–964. doi: 10.1016/j.psyneuen.2005.04.007.
    1. Ikeda H, Kiritoshi T, Murase K. Synaptic plasticity in the spinal dorsal horn. Neurosci Res. 2009;64:133–136. doi: 10.1016/j.neures.2009.03.004.
    1. Liu XG, Sandkuhler J. Long-term potentiation of C-fiber-evoked potentials in the rat spinal dorsal horn is prevented by spinal N-methyl-D-aspartic acid receptor blockage. Neurosci Lett. 1995;191:43–46. doi: 10.1016/0304-3940(95)11553-0.
    1. Liu X, Sandkuhler J. Characterization of long-term potentiation of C-fiber-evoked potentials in spinal dorsal horn of adult rat: essential role of NK1 and NK2 receptors. J Neurophysiol. 1997;78:1973–1982.
    1. Zhang HM, Zhou LJ, Hu XD, Hu NW, Zhang T, Liu XG. Acute nerve injury induces long-term potentiation of C-fiber evoked field potentials in spinal dorsal horn of intact rat. Sheng Li Xue Bao. 2004;56:591–596.
    1. Klein T, Magerl W, Hopf HC, Sandkuhler J, Treede RD. Perceptual correlates of nociceptive long-term potentiation and long-term depression in humans. J Neurosci. 2004;24:964–971. doi: 10.1523/JNEUROSCI.1222-03.2004.
    1. Klein T, Magerl W, Treede RD. Perceptual correlate of nociceptive long-term potentiation (LTP) in humans shares the time course of early-LTP. J Neurophysiol. 2006;96:3551–3555. doi: 10.1152/jn.00755.2006.
    1. Beattie EC, Stellwagen D, Morishita W, Bresnahan JC, Ha BK, Von Zastrow M, Beattie MS, Malenka RC. Control of synaptic strength by glial TNFalpha. Science. 2002;295:2282–2285. doi: 10.1126/science.1067859.
    1. Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF-alpha. Nature. 2006;440:1054–1059. doi: 10.1038/nature04671.
    1. Pickering M, Cumiskey D, O'Connor JJ. Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Exp Physiol. 2005;90:663–670. doi: 10.1113/expphysiol.2005.030734.
    1. Tancredi V, D'Arcangelo G, Grassi F, Tarroni P, Palmieri G, Santoni A, Eusebi F. Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. Neurosci Lett. 1992;146:176–178. doi: 10.1016/0304-3940(92)90071-E.
    1. Liu YL, Zhou LJ, Hu NW, Xu JT, Wu CY, Zhang T, Li YY, Liu XG. Tumor necrosis factor-alpha induces long-term potentiation of C-fiber evoked field potentials in spinal dorsal horn in rats with nerve injury: the role of NF-kappa B, JNK and p38 MAPK. Neuropharmacology. 2007;52:708–715. doi: 10.1016/j.neuropharm.2006.09.011.
    1. Holton FA, Holton P. The capillary dilator substances in dry powders of spinal roots; a possible role of adenosine triphosphate in chemical transmission from nerve endings. J Physiol. 1954;126:124–140.
    1. Holton P. The liberation of adenosine triphosphate on antidromic stimulation of sensory nerves. J Physiol. 1959;145:494–504.
    1. Bleehen T, Keele CA. Observations on the algogenic actions of adenosine compounds on the human blister base preparation. Pain. 1977;3:367–377. doi: 10.1016/0304-3959(77)90066-5.
    1. Bleehen T. The effects of adenine nucleotides on cutaneous afferent nerve activity. Br J Pharmacol. 1978;62:573–577.
    1. Jahr CE, Jessell TM. ATP excites a subpopulation of rat dorsal horn neurones. Nature. 1983;304:730–733. doi: 10.1038/304730a0.
    1. Burnstock G. Purinergic nerves and receptors. Prog Biochem Pharmacol. 1980;16:141–154.
    1. Burnstock G, Kennedy C. Is there a basis for distinguishing two types of P2-purinoceptor? Gen Pharmacol. 1985;16:433–440.
    1. Burnstock G. Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov. 2008;7:575–590. doi: 10.1038/nrd2605.
    1. Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev. 2007;87:659–797. doi: 10.1152/physrev.00043.2006.
    1. Amaya F, Wang H, Costigan M, Allchorne AJ, Hatcher JP, Egerton J, Stean T, Morisset V, Grose D, Gunthorpe MJ. The voltage-gated sodium channel Na(v)1.9 is an effector of peripheral inflammatory pain hypersensitivity. J Neurosci. 2006;26:12852–12860. doi: 10.1523/JNEUROSCI.4015-06.2006.
    1. Novakovic SD, Kassotakis LC, Oglesby IB, Smith JA, Eglen RM, Ford AP, Hunter JC. Immunocytochemical localization of P2X3 purinoceptors in sensory neurons in naive rats and following neuropathic injury. Pain. 1999;80:273–282. doi: 10.1016/S0304-3959(98)00225-5.
    1. Bradbury EJ, Burnstock G, McMahon SB. The expression of P2X3 purinoreceptors in sensory neurons: effects of axotomy and glial-derived neurotrophic factor. Mol Cell Neurosci. 1998;12:256–268. doi: 10.1006/mcne.1998.0719.
    1. Barclay J, Patel S, Dorn G, Wotherspoon G, Moffatt S, Eunson L, Abdel'al S, Natt F, Hall J, Winter J. Functional downregulation of P2X3 receptor subunit in rat sensory neurons reveals a significant role in chronic neuropathic and inflammatory pain. J Neurosci. 2002;22:8139–8147.
    1. Dorn G, Patel S, Wotherspoon G, Hemmings-Mieszczak M, Barclay J, Natt FJ, Martin P, Bevan S, Fox A, Ganju P. siRNA relieves chronic neuropathic pain. Nucleic Acids Res. 2004;32:e49. doi: 10.1093/nar/gnh044.
    1. Honore P, Kage K, Mikusa J, Watt AT, Johnston JF, Wyatt JR, Faltynek CR, Jarvis MF, Lynch K. Analgesic profile of intrathecal P2X(3) antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats. Pain. 2002;99:11–19. doi: 10.1016/S0304-3959(02)00032-5.
    1. Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, Inoue K. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature. 2003;424:778–783. doi: 10.1038/nature01786.
    1. Ulmann L, Hatcher JP, Hughes JP, Chaumont S, Green PJ, Conquet F, Buell GN, Reeve AJ, Chessell IP, Rassendren F. Up-regulation of P2X4 receptors in spinal microglia after peripheral nerve injury mediates BDNF release and neuropathic pain. J Neurosci. 2008;28:11263–11268. doi: 10.1523/JNEUROSCI.2308-08.2008.
    1. Trang T, Beggs S, Salter MW. Purinoceptors in microglia and neuropathic pain. Pflugers Arch. 2006;452:645–652. doi: 10.1007/s00424-006-0074-5.
    1. Gong QJ, Li YY, Xin WJ, Zang Y, Ren WJ, Wei XH, Zhang T, Liu XG. ATP induces long-term potentiation of C-fiber-evoked field potentials in spinal dorsal horn: the roles of P2X4 receptors and p38 MAPK in microglia. Glia. 2009;57:583–591. doi: 10.1002/glia.20786.
    1. Suzuki T, Hide I, Ido K, Kohsaka S, Inoue K, Nakata Y. Production and release of neuroprotective tumor necrosis factor by P2X7 receptor-activated microglia. J Neurosci. 2004;24:1–7. doi: 10.1523/JNEUROSCI.3792-03.2004.
    1. Lister MF, Sharkey J, Sawatzky DA, Hodgkiss JP, Davidson DJ, Rossi AG, Finlayson K. The role of the purinergic P2X7 receptor in inflammation. J Inflamm (Lond) 2007;4:5. doi: 10.1186/1476-9255-4-5.
    1. Terayama R, Omura S, Fujisawa N, Yamaai T, Ichikawa H, Sugimoto T. Activation of microglia and p38 mitogen-activated protein kinase in the dorsal column nucleus contributes to tactile allodynia following peripheral nerve injury. Neuroscience. 2008;153:1245–1255. doi: 10.1016/j.neuroscience.2008.03.041.
    1. Wen YR, Suter MR, Ji RR, Yeh GC, Wu YS, Wang KC, Kohno T, Sun WZ, Wang CC. Activation of p38 mitogen-activated protein kinase in spinal microglia contributes to incision-induced mechanical allodynia. Anesthesiology. 2009;110:155–165. doi: 10.1097/ALN.0b013e318190bc16.
    1. Crown ED, Ye Z, Johnson KM, Xu GY, McAdoo DJ, Hulsebosch CE. Increases in the activated forms of ERK 1/2, p38 MAPK, and CREB are correlated with the expression of at-level mechanical allodynia following spinal cord injury. Exp Neurol. 2006;199:397–407. doi: 10.1016/j.expneurol.2006.01.003.
    1. Crown ED, Gwak YS, Ye Z, Johnson KM, Hulsebosch CE. Activation of p38 MAP kinase is involved in central neuropathic pain following spinal cord injury. Exp Neurol. 2008;213:257–267. doi: 10.1016/j.expneurol.2008.05.025.
    1. Schafers M, Svensson CI, Sommer C, Sorkin LS. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci. 2003;23:2517–2521.
    1. Sun M, Fink PJ. A new class of reverse signaling costimulators belongs to the TNF family. J Immunol. 2007;179:4307–4312.
    1. Hao S, Mata M, Glorioso JC, Fink DJ. Gene transfer to interfere with TNFalpha signaling in neuropathic pain. Gene Ther. 2007;14:1010–1016. doi: 10.1038/sj.gt.3302950.
    1. Mata M, Hao S, Fink DJ. Gene therapy directed at the neuroimmune component of chronic pain with particular attention to the role of TNF alpha. Neurosci Lett. 2008;437:209–213. doi: 10.1016/j.neulet.2008.03.049.
    1. Shamji MF, Chen J, Friedman AH, Richardson WJ, Chilkoti A, Setton LA. Synthesis and characterization of a thermally-responsive tumor necrosis factor antagonist. J Control Release. 2008;129:179–186. doi: 10.1016/j.jconrel.2008.04.021.
    1. Shamji MF, Jing L, Chen J, Hwang P, Ghodsizadeh O, Friedman AH, Richardson WJ, Setton LA. Treatment of neuroinflammation by soluble tumor necrosis factor receptor Type II fused to a thermally responsive carrier. J Neurosurg Spine. 2008;9:221–228. doi: 10.3171/SPI/2008/9/7/010.
    1. Sommer C, Lindenlaub T, Teuteberg P, Schafers M, Hartung T, Toyka KV. Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy. Brain Res. 2001;913:86–89. doi: 10.1016/S0006-8993(01)02743-3.
    1. Lindenlaub T, Teuteberg P, Hartung T, Sommer C. Effects of neutralizing antibodies to TNF-alpha on pain-related behavior and nerve regeneration in mice with chronic constriction injury. Brain Res. 2000;866:15–22. doi: 10.1016/S0006-8993(00)02190-9.
    1. Sommer C, Schafers M, Marziniak M, Toyka KV. Etanercept reduces hyperalgesia in experimental painful neuropathy. J Peripher Nerv Syst. 2001;6:67–72. doi: 10.1046/j.1529-8027.2001.01010.x.
    1. Svensson CI, Schafers M, Jones TL, Powell H, Sorkin LS. Spinal blockade of TNF blocks spinal nerve ligation-induced increases in spinal P-p38. Neurosci Lett. 2005;379:209–213. doi: 10.1016/j.neulet.2004.12.064.
    1. Marchand F, Tsantoulas C, Singh D, Grist J, Clark AK, Bradbury EJ, McMahon SB. Effects of Etanercept and Minocycline in a rat model of spinal cord injury. Eur J Pain. 2009;13:673–681. doi: 10.1016/j.ejpain.2008.08.001.
    1. Si Q, Nakamura Y, Ogata T, Kataoka K, Schubert P. Differential regulation of microglial activation by propentofylline via cAMP signaling. Brain Res. 1998;812:97–104. doi: 10.1016/S0006-8993(98)00954-8.
    1. Sweitzer SM, Schubert P, DeLeo JA. Propentofylline, a glial modulating agent, exhibits antiallodynic properties in a rat model of neuropathic pain. J Pharmacol Exp Ther. 2001;297:1210–1217.
    1. Tawfik VL, Nutile-McMenemy N, Lacroix-Fralish ML, Deleo JA. Efficacy of propentofylline, a glial modulating agent, on existing mechanical allodynia following peripheral nerve injury. Brain Behav Immun. 2007;21:238–246. doi: 10.1016/j.bbi.2006.07.001.
    1. Mielke R, Moller HJ, Erkinjuntti T, Rosenkranz B, Rother M, Kittner B. Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials. Alzheimer Dis Assoc Disord. 1998;12(Suppl 2):S29–35.
    1. Frampton M, Harvey RJ, Kirchner V. Propentofylline for dementia. Cochrane Database Syst Rev. 2003. p. CD002853.
    1. Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut. 2002;50:196–200. doi: 10.1136/gut.50.2.196.
    1. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177:1675–1680. doi: 10.1084/jem.177.6.1675.
    1. Sommer C, Marziniak M, Myers RR. The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve. Pain. 1998;74:83–91. doi: 10.1016/S0304-3959(97)00154-1.
    1. George A, Marziniak M, Schafers M, Toyka KV, Sommer C. Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin. Pain. 2000;88:267–275. doi: 10.1016/S0304-3959(00)00333-X.
    1. Mackey S, Feinberg S. Pharmacologic therapies for complex regional pain syndrome. Curr Pain Headache Rep. 2007;11:38–43. doi: 10.1007/s11916-007-0020-z.
    1. Goli V. Does thalidomide have an analgesic effect? Current status and future directions. Curr Pain Headache Rep. 2007;11:109–114. doi: 10.1007/s11916-007-0007-9.
    1. Clemmensen OJ, Olsen PZ, Andersen KE. Thalidomide neurotoxicity. Arch Dermatol. 1984;120:338–341. doi: 10.1001/archderm.120.3.338.
    1. el-Badawi MG, Fatani JA, Bahakim H, Abdalla MA. Light and electron microscopic observations on the cerebellum of guinea pigs following low-dose methotrexate. Exp Mol Pathol. 1990;53:211–222. doi: 10.1016/0014-4800(90)90045-F.
    1. Montesinos MC, Takedachi M, Thompson LF, Wilder TF, Fernandez P, Cronstein BN. The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5'-nucleotidase: findings in a study of ecto-5'-nucleotidase gene-deficient mice. Arthritis Rheum. 2007;56:1440–1445. doi: 10.1002/art.22643.
    1. Montesinos MC, Yap JS, Desai A, Posadas I, McCrary CT, Cronstein BN. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum. 2000;43:656–663. doi: 10.1002/1529-0131(200003)43:3<656::AID-ANR23>;2-H.
    1. Segal R, Mozes E, Yaron M, Tartakovsky B. The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum. 1989;32:370–377. doi: 10.1002/anr.1780320403.
    1. Hashizume H, Rutkowski MD, Weinstein JN, DeLeo JA. Central administration of methotrexate reduces mechanical allodynia in an animal model of radiculopathy/sciatica. Pain. 2000;87:159–169. doi: 10.1016/S0304-3959(00)00281-5.
    1. Bruce-Gregorios JH, Soucy D, Chen MG, Benson N. Effect of methotrexate on cell cycle and DNA synthesis of astrocytes in primary culture: flow cytometric studies. J Neuropathol Exp Neurol. 1991;50:63–72. doi: 10.1097/00005072-199101000-00005.
    1. Bruce-Gregorios JH, Soucy DM, Chen MG, Norenberg MD. Effect of methotrexate on glial fibrillary acidic protein content of astrocytes in primary culture. J Neuropathol Exp Neurol. 1991;50:118–125. doi: 10.1097/00005072-199103000-00003.
    1. Gregorios JB, Gregorios AB, Mora J, Marcillo A, Fojaco RM, Green B. Morphologic alterations in rat brain following systemic and intraventricular methotrexate injection: light and electron microscopic studies. J Neuropathol Exp Neurol. 1989;48:33–47. doi: 10.1097/00005072-198901000-00004.
    1. Genevay S, Finckh A, Payer M, Mezin F, Tessitore E, Gabay C, Guerne PA. Elevated levels of tumor necrosis factor-alpha in periradicular fat tissue in patients with radiculopathy from herniated disc. Spine. 2008;33:2041–2046. doi: 10.1097/BRS.0b013e318183bb86.
    1. Genevay S, Stingelin S, Gabay C. Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study. Ann Rheum Dis. 2004;63:1120–1123. doi: 10.1136/ard.2003.016451.
    1. Karppinen J, Korhonen T, Malmivaara A, Paimela L, Kyllonen E, Lindgren KA, Rantanen P, Tervonen O, Niinimaki J, Seitsalo S, Hurri H. Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica. Spine. 2003;28:750–753. doi: 10.1097/00007632-200304150-00004. discussion 753-754.
    1. Korhonen T, Karppinen J, Malmivaara A, Autio R, Niinimaki J, Paimela L, Kyllonen E, Lindgren KA, Tervonen O, Seitsalo S, Hurri H. Efficacy of infliximab for disc herniation-induced sciatica: one-year follow-up. Spine. 2004;29:2115–2119. doi: 10.1097/01.brs.0000141179.58778.6c.
    1. Korhonen T, Karppinen J, Paimela L, Malmivaara A, Lindgren KA, Jarvinen S, Niinimaki J, Veeger N, Seitsalo S, Hurri H. The treatment of disc herniation-induced sciatica with infliximab: results of a randomized, controlled, 3-month follow-up study. Spine. 2005;30:2724–2728. doi: 10.1097/01.brs.0000190815.13764.64.
    1. Korhonen T, Karppinen J, Paimela L, Malmivaara A, Lindgren KA, Bowman C, Hammond A, Kirkham B, Jarvinen S, Niinimaki J. The treatment of disc-herniation-induced sciatica with infliximab: one-year follow-up results of FIRST II, a randomized controlled trial. Spine. 2006;31:2759–2766. doi: 10.1097/01.brs.0000245873.23876.1e.
    1. Cohen SP, Wenzell D, Hurley RW, Kurihara C, Buckenmaier CC, Griffith S, Larkin TM, Dahl E, Morlando BJ. A double-blind, placebo-controlled, dose-response pilot study evaluating intradiscal etanercept in patients with chronic discogenic low back pain or lumbosacral radiculopathy. Anesthesiology. 2007;107:99–105. doi: 10.1097/01.anes.0000267518.20363.0d.
    1. Cohen SP, Bogduk N, Dragovich A, Buckenmaier CC, Griffith S, Kurihara C, Raymond J, Richter PJ, Williams N, Yaksh TL. Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica. Anesthesiology. 2009;110:1116–1126. doi: 10.1097/ALN.0b013e3181a05aa0.
    1. Rolan P, Gibbons JA, He L, Chang E, Jones D, Gross MI, Davidson JB, Sanftner LM, Johnson KW. Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses. Br J Clin Pharmacol. 2008;66:792–801. doi: 10.1111/j.1365-2125.2008.03270.x.
    1. Ledeboer A, Liu T, Shumilla JA, Mahoney JH, Vijay S, Gross MI, Vargas JA, Sultzbaugh L, Claypool MD, Sanftner LM. The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol. 2006;2:279–291. doi: 10.1017/S1740925X0700035X.
    1. Watkins LR, Milligan ED, Maier SF. Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. Adv Exp Med Biol. 2003;521:1–21.
    1. Wieseler-Frank J, Maier SF, Watkins LR. Glial activation and pathological pain. Neurochem Int. 2004;45:389–395. doi: 10.1016/j.neuint.2003.09.009.
    1. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci. 2009;10:23–36. doi: 10.1038/nrn2533.
    1. Milligan ED, Sloane EM, Watkins LR. Glia in pathological pain: a role for fractalkine. J Neuroimmunol. 2008;198:113–120. doi: 10.1016/j.jneuroim.2008.04.011.
    1. Bettoni I, Comelli F, Rossini C, Granucci F, Giagnoni G, Peri F, Costa B. Glial TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in mice. Glia. 2008;56:1312–1319. doi: 10.1002/glia.20699.
    1. Schafers M, Sommer C. Anticytokine therapy in neuropathic pain management. Expert Rev Neurother. 2007;7:1613–1627. doi: 10.1586/14737175.7.11.1613.
    1. Gao YJ, Ji RR. Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol Ther. 2010;126(1):56–68. doi: 10.1016/j.pharmthera.2010.01.002.
    1. Ji RR, Gereau RWt, Malcangio M, Strichartz GR. MAP kinase and pain. Brain Res Rev. 2008;60(1):135–48. doi: 10.1016/j.brainresrev.2008.12.011.
    1. Ledeboer A, Hutchinson MR, Watkins LR, Johnson KW. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin Investig Drugs. 2007;16:935–950. doi: 10.1517/13543784.16.7.935.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다